TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: BMI-sds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intake of unhealthy foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general voice problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specific voice problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phonation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in immediate memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in delayed memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of hs‐CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood levels of IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood levels of IL‐1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IDS-C score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythema of surgical wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Vertical scar size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wound infection incidence
Endpoint domain: Adverse events/effects
Primary endpoint: ED visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Admissions from the ED
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Development of akathisia
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective restlessness
Endpoint domain: Adverse events/effects
Primary endpoint: Neuromuscular potency of vecuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal numeric scale values for pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in daily incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale reduction in urinary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores for atypical depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement factor in facial angiofibromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability assessment of intubation tubes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Loss in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in treating melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of oxidative stress and muscle damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma C-reactive protein (CRP) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: arbitrary inflammatory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma interleukin-6 (IL-6) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recurrent MI
Endpoint domain: Mortality/survival
Primary endpoint: Plasma potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall work impairment because of health
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diabetes resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: combined end-point (any death or nonfatal myocardial infarction or nonfatal stroke)
Endpoint domain: Mortality/survival
Primary endpoint: ANCA seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caffeine clearance correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CYP1A2 activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lifestyle-related deaths
Endpoint domain: Mortality/survival
Primary endpoint: Major disability resulting in limitations of work or daily activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: CDVA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IOP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving ≤ 50% reduction from baseline in seizure frequency/28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance reached in the anterior direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI Z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Excess body weight lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of postoperative nausea and vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients free from postoperative nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight change at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ApoA1/Apo B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid metabolism outcomes
Primary endpoint: Lp-PLA2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Montgomery Asberg Depression Rating Scale change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC function scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improved position sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: PSMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent health-promoting behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Retention during phacoemulsification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ease of removal after IOL implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of metaphase II oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of metaphase II oocytes with mature cytoplasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of metaphase II oocytes with mature cytoplasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Serum levels of matrix metalloproteinases‐2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of tumour necrosis factor alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of high‐sensitivity C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form‐12 Mental Component Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reductions in TAU outpatient visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: days' supply of all medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reduction of upper-limb hypertonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fugl-Meyer assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Barthel index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first event of repeat revascularization, myocardial infarction, stroke, or cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Knee adduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Speed of walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative incisional pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Up-to-date coverage rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct use rates after 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall error rates
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in patient state anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improved swallowing related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in food residues in the pharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding after tonsillectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: complete obliterations of intracranial aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite of death, clinical re-infarction, or disabling stroke
Endpoint domain: Mortality/survival
Primary endpoint: Mean femoral tunnel length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PNIF improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: sensory amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Attendance at the 7-day post-operative clinic visit
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: composite event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive attitudes toward clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aortic regurgitation prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitral regurgitation prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in MBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instructor overall evaluation of student skill station performance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participant overall feedback on all components of the course
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: success rates of teeth obturated with ZOE and Calen(®) /ZO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean postoperative range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean KSS clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean KSS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication domain of neurodevelopment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal thickness (CT) variation during WDT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-hematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity of the MB11 BERAphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of the MB11 BERAphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean MB11 BERAphone test time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cholesterol concentration in LDL3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol load per particle in LDL3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Particle number of LDL3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration time curve (AUC(infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean GGT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported alcohol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuing pregnancy at initial follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Complete abortion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response time (RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician-rated improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject preference for inhaler
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sperm density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 5-year recurrence-free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: HbA1c concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HOMA-IR values improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose metabolic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HBV DNA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of shoulder and elbow injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Participant completion rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Interventionist fidelity to the protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area under the plasma-time curve (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin moisture content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction of fine lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of endometriosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of RS (Recurrent Symptoms)
Endpoint domain: Adverse events/effects
Primary endpoint: Total health care costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: EQ-5D-3L index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: maximum volume reduction in masseter hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of nocturnal blood pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean probing depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative horizontal clinical attachment level (CAL) gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: defect depth reduction (DDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perception of itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: disability 15 months postpartum
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean plasma HIV-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 production by PMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Little's irregularity indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intercanine widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower incisor inclinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient tolerance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: workdays lost
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: disability days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: circulating T cell restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: asthma symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: use of short acting beta 1 agonists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anaerobic threshold point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean OFF time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hookworm prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean hookworm infection in eggs/gram of stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: relative risk of hookworm infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative refraction error (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stable response (> or = 50% decrease on the HAMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stable remission (HAMD score of < or = 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to onset of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary cortisol:creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum concentrations of TNF‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum concentrations of NO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Firmicutes to Bacteroidetes ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of susceptibility artefacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Taste-related activation in orbitofrontal and insular cortices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Developmental quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand and eye coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrheal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: RBC proportion of arachidonic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LTL (telomere length)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC pain change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Circulating free fatty acids (FFA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall recall rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incorporation of EPA in liver tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incorporation of DHA in liver tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes